Overview

Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study

Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
The primary study hypothesis of this study is to determine whether there is a greater percentage of patients achieving a triglyceride level of <200 mg/dL with the combination of simvastatin 20 mg and fenofibrate 160mg than with either simvastatin 20 mg monotherapy or fenofibrate 160mg monotherapy.
Phase:
N/A
Details
Lead Sponsor:
Intermountain Health Care, Inc.
Collaborators:
Abbott
Merck Sharp & Dohme Corp.
Treatments:
Fenofibrate
Simvastatin